2023
Biomechanical effect of neurologic dance training (NDT) for breast cancer survivors with chemotherapy-induced neuropathy: study protocol for a randomized controlled trial and preliminary baseline data
Lantis K, Schnell P, Bland C, Wilder J, Hock K, Vargo C, Glover N, Hackney M, Lustberg M, Worthen-Chaudhari L. Biomechanical effect of neurologic dance training (NDT) for breast cancer survivors with chemotherapy-induced neuropathy: study protocol for a randomized controlled trial and preliminary baseline data. Trials 2023, 24: 564. PMID: 37658464, PMCID: PMC10472642, DOI: 10.1186/s13063-023-07554-z.Peer-Reviewed Original ResearchConceptsChemotherapy-induced neuropathyPhysical activityBackgroundBreast cancerOutcome measuresNon-pharmacologic interventionsBreast cancer survivorsPrimary outcome measureHome exercise interventionQuality of lifeControl intervention groupPreliminary baseline dataPrimary endpointExercise interventionBC survivorsTertiary outcomesCancer survivorsSensorimotor symptomsClinical trialsIntervention groupTwo-armWeek 8Mean changeFall riskPrimary estimandTreatment groupsIdentification of a SNP cluster associated with taxane-induced peripheral neuropathy risk in patients being treated for breast cancer using GWAS data derived from a large cooperative group trial
Lustberg M, Wu X, Fernández-Martínez J, de Andrés-Galiana E, Philips S, Leibowitz J, Schneider B, Sonis S. Identification of a SNP cluster associated with taxane-induced peripheral neuropathy risk in patients being treated for breast cancer using GWAS data derived from a large cooperative group trial. Supportive Care In Cancer 2023, 31: 139. PMID: 36707490, DOI: 10.1007/s00520-023-07595-9.Peer-Reviewed Original ResearchConceptsChemotherapy-induced peripheral neuropathyLarge cooperative group trialsCooperative group trialsIndependent patient cohortsCancer chemotherapy regimenCIPN riskCommon toxicitiesTaxane exposureChemotherapy regimenNeuropathy riskPeripheral neuropathyPatient cohortClinical trialsBreast cancerGroup trialsEffective interventionsPatientsRisk determinationInconsistent resultsECoGTrialsPresent studyRiskDiscriminatory powerHigh predictive accuracy
2022
Right Sizing Systemic Therapy for Patients with Breast Cancer. Where are we Today?
Williams N, Grimm M, Gast K, Lustberg M. Right Sizing Systemic Therapy for Patients with Breast Cancer. Where are we Today? Current Breast Cancer Reports 2022, 14: 142-152. DOI: 10.1007/s12609-022-00463-1.Peer-Reviewed Original ResearchEarly-stage breast cancerBreast cancerSystemic therapyClinical outcomesER-positive breast cancerTriple-negative breast cancerBreast cancer supportRobust clinical outcomesOptimized clinical outcomesQuality of lifePersonalized medicine approachNeoadjuvant regimensAdditional therapyEndocrine therapySelect patientsClinical trialsBest therapyPrognostic biomarkerPatientsCancer supportTherapyMedicine approachCancerRoutine useGenomic testingPsychological Distress in Young Adults with Acute Myeloid Leukemia Undergoing Induction Chemotherapy
Lockwood B, El-Jawahri A, Walker A, Ehrman S, Russell D, Kale S, Gustin J, Bose-Brill S, LeBlanc T, Luger S, Lustberg M, Bhatnagar B. Psychological Distress in Young Adults with Acute Myeloid Leukemia Undergoing Induction Chemotherapy. Journal Of Adolescent And Young Adult Oncology 2022, 12: 592-598. PMID: 36367711, DOI: 10.1089/jayao.2022.0082.Peer-Reviewed Original ResearchConceptsYoung adultsHigh-risk AMLUnpredictable illness trajectoriesPatient-reported outcomesHospitalized young adultsHighest post-traumatic stress disorderPost-traumatic stress disorderInduction chemotherapyIntensive chemotherapyUnmet psychological needsClinical trialsIllness trajectoryWeek 2Secondary analysisStress disorderOlder adultsPsychological distressLife disruptionChemotherapyWorse qualityAdultsAMLHigh anxietyAnxietyHospitalizationThe mutational profile of ER-, PR+, HER2- metastatic breast cancer.
Fischbach N, Huang R, Lustberg M, Pelletier M, Pusztai L, Sivakumar S, Sokol E, Ross J, Levy M. The mutational profile of ER-, PR+, HER2- metastatic breast cancer. Journal Of Clinical Oncology 2022, 40: 1025-1025. DOI: 10.1200/jco.2022.40.16_suppl.1025.Peer-Reviewed Original ResearchTriple-negative breast cancerComprehensive genomic profilingMetastatic breast cancerBreast cancerClinical trialsPathology reportsMutational profileHER2- metastatic breast cancerConsecutive breast cancersAnti-estrogen therapyNegative breast cancerPD-L1 IHCPotential therapeutic implicationsHigh rateEndocrine therapyEstrogen therapyPatient ageFoundation MedicineKRAS alterationsRare subtypeHER2 expressionClinical behaviorReceptor phenotypeBreast carcinomaTreatment strategiesTreatment patterns and medical costs of metastatic breast cancer care in the United States.
Jaber Chehayeb R, Hood A, Mougalian S, Lustberg M, Wang S, Greenup R, Pusztai L, Kunst N. Treatment patterns and medical costs of metastatic breast cancer care in the United States. Journal Of Clinical Oncology 2022, 40: e18834-e18834. DOI: 10.1200/jco.2022.40.16_suppl.e18834.Peer-Reviewed Original ResearchMetastatic breast cancerTreatment patternsTreatment costsDiagnosis of MBCSocietal perspectiveHormone receptor statusBreast cancer careDays of diagnosisDe-identified databaseAverage wholesale priceElectronic health recordsMBC patientsMBC diagnosisReceptor statusCancer careInvasive cancerTriple NegativeClinical trialsReceptor subtypesPatient levelBreast cancerHuman epidermal growth factorPayer perspectiveDrug costsEpidermal growth factor
2021
Emerging Pharmacological and Non-Pharmacological Therapeutics for Prevention and Treatment of Chemotherapy-Induced Peripheral Neuropathy
Li Y, Lustberg MB, Hu S. Emerging Pharmacological and Non-Pharmacological Therapeutics for Prevention and Treatment of Chemotherapy-Induced Peripheral Neuropathy. Cancers 2021, 13: 766. PMID: 33673136, PMCID: PMC7918689, DOI: 10.3390/cancers13040766.Peer-Reviewed Original ResearchChemotherapy-induced peripheral neuropathyPeripheral neuropathyPathogenesis of CIPNTreatment of CIPNFirst-line chemotherapeutic agentNon-pharmacological therapeuticsCommon adverse eventsNon-pharmacological strategiesQuality of lifeAdverse eventsClinical outcomesCancer survivorsEffective intervention strategiesClinical trialsSide effectsChemotherapeutic agentsEffective interventionsVinca alkaloidsNew targetsIntervention strategiesNeuropathyPrior failureClinical researchersPlatinum compoundsTherapeutics
2018
Remarkable response to a novel ATR inhibitor in a patient with poorly differentiated neuroendocrine carcinoma.
Saito Y, Li Z, Lustberg M, Grenade C, Wesolowski R. Remarkable response to a novel ATR inhibitor in a patient with poorly differentiated neuroendocrine carcinoma. Cancer Treatment And Research Communications 2018, 16: 9-12. PMID: 31299005, DOI: 10.1016/j.ctarc.2018.04.001.Peer-Reviewed Original ResearchNeuroendocrine carcinomaExceptional responseLarge cell neuroendocrine carcinomaEarly phase clinical trialsProgression-free survivalMetastatic prostate cancerCell neuroendocrine carcinomaNumber of malignanciesPrimary human tumorsMechanism of actionCancer cell linesFree survivalCell cycle arrestClinical trialsProstate cancerDNA damaging drugsNovel ATR inhibitorPatientsHuman tumorsM6620Cytotoxic effectsCycle arrestRemarkable responseDamaging drugsClonal evolutionImplementing Liquid Biopsies in Clinical Trials
Lustberg M, Stover D, Chalmers J. Implementing Liquid Biopsies in Clinical Trials. The Cancer Journal 2018, 24: 61-64. PMID: 29601331, PMCID: PMC5880324, DOI: 10.1097/ppo.0000000000000309.Peer-Reviewed Original ResearchConceptsClinical trialsLiquid biopsyReal-time biopsySurrogate efficacy endpointsTreatment response evaluationMultiple clinical trialsRoutine clinical practiceCell-free DNATumor-specific biomarkersEfficacy endpointBlood markersPredictive biomarkersPharmacodynamic biomarkersPrognostic biomarkerTreatment selectionTumor markersBiopsyClinical practiceDisease statusTumor cellsResponse evaluationAdditional studiesBiomarkersTrialsExtracellular vesicles
2015
Neoadjuvant Dual HER2‐Targeted Therapy With Lapatinib and Trastuzumab Improves Pathologic Complete Response in Patients With Early Stage HER2‐Positive Breast Cancer: A Meta‐Analysis of Randomized Prospective Clinical Trials
Hicks M, Macrae E, Abdel‐Rasoul M, Layman R, Friedman S, Querry J, Lustberg M, Ramaswamy B, Mrozek E, Shapiro C, Wesolowski R. Neoadjuvant Dual HER2‐Targeted Therapy With Lapatinib and Trastuzumab Improves Pathologic Complete Response in Patients With Early Stage HER2‐Positive Breast Cancer: A Meta‐Analysis of Randomized Prospective Clinical Trials. The Oncologist 2015, 20: 337-343. PMID: 25732265, PMCID: PMC4391765, DOI: 10.1634/theoncologist.2014-0334.Peer-Reviewed Original ResearchConceptsAddition of lapatinibHER2-positive breast cancerNeoadjuvant chemotherapyBreast cancerLymph nodesClinical trialsEarly-stage HER2-positive breast cancerSan Antonio Breast Cancer SymposiumPathologic complete response rateEarly-stage breast cancerResidual invasive cancerResidual invasive carcinomaComplete response rateOperable breast cancerAxillary lymph nodesPathologic complete responseProspective clinical trialsStage breast cancerRates of pCRDual HER2NAC armProspective RCTsCancer SymposiumPCR rateComplete response
2010
Epigenetic Therapy in Breast Cancer
Lustberg M, Ramaswamy B. Epigenetic Therapy in Breast Cancer. Current Breast Cancer Reports 2010, 3: 34-43. PMID: 23097683, PMCID: PMC3477864, DOI: 10.1007/s12609-010-0034-0.Peer-Reviewed Original ResearchEpigenetic changesHistone deacetylase inhibitorsMajor epigenetic changesNucleosome remodelingHistone modificationsEpigenetic regulationEpigenetic mechanismsDNA methylationGene sequencesEpigenetic therapyGene expressionDemethylating agentDeacetylase inhibitorsMultistep processBreast cancerEpigeneticsBreast carcinogenesisGenesMethylationSystemic therapyClinical trialsEffective therapyReversible processRegulationSingle agent